Abstract
Key Questions
1. What is the significance of cardiac biomarkers in glomerulonephritis (GN)?
Cardiac biomarkers like Troponin I and NT-proBNP provide prognostic information for major adverse cardiovascular events (MACE) in GN patients.
2. Can cardiac biomarkers predict cardiovascular risks in GN patients?
Yes, elevated levels of Troponin I and NT-proBNP are significantly associated with increased risk of MACE within 5 years of GN diagnosis.
3. How can these biomarkers be used in clinical practice?
Biomarkers can be incorporated into cardiovascular risk profiling to guide monitoring and management strategies for GN patients.
4. What are the limitations of using these biomarkers?
The study highlights potential data errors, limited external validity, and the retrospective nature of the analysis as limitations.
Abstract
Background
Glomerulonephritis (GN) is a leading cause of chronic kidney disease (CKD) and is associated with a high risk of major adverse cardiovascular events (MACE). This study investigates the prognostic role of cardiac biomarkers Troponin I and NT-proBNP in predicting MACE within 5 years of GN diagnosis.
Methods
A retrospective cohort analysis using the TriNetX global health research network evaluated the significance of Troponin I and NT-proBNP thresholds in predicting MACE. Propensity score matching and Cox proportional hazard models were applied for analysis.
Results
In the Troponin I cohort (n=34,974), 9% experienced MACE (HR 1.79, p<0.0001). In the NT-proBNP cohort (n=18,218), 9% experienced MACE (HR 1.99, p<0.0001). Both biomarkers were predictive of all-cause mortality, heart failure, and other cardiovascular events.
Conclusion
Routine measurement of cardiac biomarkers can aid in cardiovascular and mortality risk profiling for GN patients, highlighting the importance of incorporating these into clinical management.
